Bivamelagon (INNTooltip International Nonproprietary Name; developmental code names LB54640, LR-19021) is a small-molecule melanocortin MC4 receptor agonist under development by LG Chem Life Sciences for the treatment of hypothalamic obesity, .

[1][2] Unlike the older drug with the same mechanism of action, setmelanotide, it can be taken orally.

[3][4][5] As of March 2024, it is in phase 2 clinical trials.

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.